BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, Arce VM. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. 2002;12:31-38. [PMID: 11914546 DOI: 10.1159/000047824] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Callison JC Jr, Walker RC, Massion PP. Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. J Lung Cancer 2011;10:69-76. [PMID: 25663834 DOI: 10.6058/jlc.2011.10.2.69] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lang F, Gulbins E, Szabo I, Vereninov A, Huber SM. Ion Channels, Cell Volume, Cell Proliferation and Apoptotic Cell Death. In: Martinac B, editor. Sensing with Ion Channels. Berlin: Springer Berlin Heidelberg; 2008. pp. 69-84. [DOI: 10.1007/978-3-540-72739-2_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother 2016;17:1631-42. [PMID: 27352098 DOI: 10.1080/14656566.2016.1199687] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
4 Bläker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Bröring DC, Pace A, Greten H, De Weerth A. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol. 2004;41:112-118. [PMID: 15246216 DOI: 10.1016/j.jhep.2004.03.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
5 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
6 Guillermet-guibert J, Saint-laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways. Cell Death Differ 2007;14:197-208. [DOI: 10.1038/sj.cdd.4401939] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
7 Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 2010;14:2570-84. [PMID: 20629989 DOI: 10.1111/j.1582-4934.2010.01125.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
8 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
9 Guillermet-Guibert J, Lahlou H, Pyronnet S, Bousquet C, Susini C. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535-51. [PMID: 16183526 DOI: 10.1016/j.bpg.2005.03.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
10 Mastrodimou N, Lambrou GN, Thermos K. Effect of somatostatin analogues on chemically induced ischaemia in the rat retina. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:44-53. [PMID: 15645293 DOI: 10.1007/s00210-004-1011-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
11 Petrović-Djergović DM, Rakin AK, Kustrimović NZ, Ristovski JS, Dimitrijevic LA, Mileva MV. Somatostatin modulates T cells development in adult rat thymus. Regul Pept 2007;142:101-10. [PMID: 17391781 DOI: 10.1016/j.regpep.2007.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32:247-71. [PMID: 21123741 DOI: 10.1210/er.2010-0002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 140] [Article Influence: 15.0] [Reference Citation Analysis]
13 Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res 2009;28:142. [PMID: 19887008 DOI: 10.1186/1756-9966-28-142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Casarini APM, Pinto EM, Jallad RS, Giorgi RR, Giannella-neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29:826-30. [DOI: 10.1007/bf03347378] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
15 Janson E, Öberg K. Neuroendocrine tumors—somatostatin receptor expression and somatostatin analog treatment. Elsevier; 2003. pp. 535-46. [DOI: 10.1016/s0921-4410(03)21025-5] [Cited by in Crossref: 14] [Article Influence: 0.8] [Reference Citation Analysis]
16 Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L, Susini C. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004;36 Suppl 1:S2-S7. [PMID: 15077905 DOI: 10.1016/j.dld.2003.11.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
17 Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006;65:120-5. [PMID: 16479142 DOI: 10.1159/000091408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
18 Yao Q, Liu Q, Xu H, Wu Z, Zhou L, Gu Z, Gong P, Shen J. Upregulated Expression of SSTR3 is Involved in Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats. Cell Mol Neurobiol 2017;37:1407-16. [DOI: 10.1007/s10571-017-0471-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Portela-Gomes GM, Hacker GW, Weitgasser R. Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol 2004;12:183-92. [PMID: 15551729 DOI: 10.1097/00129039-200409000-00001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
20 Voisin T, Firar AE, Avondo V, Laburthe M. Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor. Endocrinology 2006;147:4977-84. [PMID: 16857748 DOI: 10.1210/en.2006-0201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
21 Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep 2017;7:40822. [PMID: 28094316 DOI: 10.1038/srep40822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
22 Kumar Nagarajan S, Babu S, Sohn H, Devaraju P, Madhavan T. Toward a better understanding of the interaction between somatostatin receptor 2 and its ligands: a structural characterization study using molecular dynamics and conceptual density functional theory. J Biomol Struct Dyn 2019;37:3081-102. [PMID: 30079808 DOI: 10.1080/07391102.2018.1508368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Lang F, Lang KS, Wieder T, Myssina S, Birka C, Lang PA, Kaiser S, Kempe D, Duranton C, Huber SM. Cation channels, cell volume and the death of an erythrocyte. Pflugers Arch 2003;447:121-5. [PMID: 12905029 DOI: 10.1007/s00424-003-1150-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
24 Inoue S, Nambu T, Shimomura T. The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures. Journal of Investigative Dermatology 2004;122:565-73. [DOI: 10.1046/j.0022-202x.2004.12628.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
25 Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol 2007;18:79-85. [PMID: 17916997 DOI: 10.1007/s12022-007-0014-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
26 Zhou T, Xiao X, Xu B, Li H, Zou Y. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways. Acta Oncologica 2009;48:401-10. [DOI: 10.1080/02841860802314746] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
27 Yuan D, Shen J, Yan Y, Wu X, Li A, Guo A, Wu Y, Duan C, Shen J, Tang C, Zhang D, Ji Y. Upregulated expression of SSTR1 is involved in neuronal apoptosis and is coupled to the reduction of bcl-2 following intracerebral hemorrhage in adult rats. Cell Mol Neurobiol 2014;34:951-61. [PMID: 25035058 DOI: 10.1007/s10571-014-0081-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
28 Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 2009;18:1297-316. [PMID: 19678799 DOI: 10.1517/13543780903176399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
29 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Hosono T, Bando M, Mizushina Y, Sata M, Hagiwara K, Sugiyama Y. Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis. Exp Lung Res 2021;47:280-8. [PMID: 33899633 DOI: 10.1080/01902148.2021.1916650] [Reference Citation Analysis]
31 Spangelo BL, Pompilius M, Farrimond DD, Stevens N, Nieva R, Shroff S, Badamchian M, Johnson CR, Jarvis WD. Presence of a peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells. Int Immunopharmacol 2005;5:1317-29. [PMID: 15914336 DOI: 10.1016/j.intimp.2005.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
32 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 134] [Article Influence: 21.3] [Reference Citation Analysis]
33 Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T. Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem 2004;279:45875-86. [PMID: 15310763 DOI: 10.1074/jbc.M404136200] [Cited by in Crossref: 73] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
34 Wang JH, Xing QT, Yuan MB. Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro. World J Gastroenterol 2004;10:1043-6. [PMID: 15052690 DOI: 10.3748/wjg.v10.i7.1043] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Voisin T, Firar AE, Rouyer‐fessard C, Gratio V, Laburthe M. A hallmark of immunoreceptor, the tyrosine‐based inhibitory motif ITIM, is present in the G protein‐coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB j 2008;22:1993-2002. [DOI: 10.1096/fj.07-098723] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
36 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Reference Citation Analysis]
37 Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017. [PMID: 14654798 DOI: 10.1038/nrd1255] [Cited by in Crossref: 379] [Cited by in F6Publishing: 329] [Article Influence: 22.3] [Reference Citation Analysis]
38 Lang F, Foller M, Lang KS, Lang PA, Ritter M, Gulbins E, Vereninov A, Huber SM. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol. 2005;205:147-157. [PMID: 16362503 DOI: 10.1007/s00232-005-0780-5] [Cited by in Crossref: 237] [Cited by in F6Publishing: 207] [Article Influence: 15.8] [Reference Citation Analysis]
39 Lin X, Wang YJ, Li Q, Hou YY, Hong MH, Cao YL, Chi ZQ, Liu JG. Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J. 2009;276:2022-2036. [PMID: 19292871 DOI: 10.1111/j.1742-4658.2009.06938.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
40 Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131. [PMID: 15153426 DOI: 10.1196/annals.1294.012] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 6.4] [Reference Citation Analysis]
41 Lang F, Huber SM, Szabo I, Gulbins E. Plasma membrane ion channels in suicidal cell death. Arch Biochem Biophys 2007;462:189-94. [PMID: 17316548 DOI: 10.1016/j.abb.2006.12.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
42 Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 2004;52:391-400. [PMID: 14966206 DOI: 10.1177/002215540405200310] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
43 Ferone D, van Hagen P, Semino C, Dalm V, Barreca A, Colao A, Lamberts S, Minuto F, Hofland L. Somatostatin receptor distribution and function in immune system. Digestive and Liver Disease 2004;36:S68-77. [DOI: 10.1016/j.dld.2003.11.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
44 Zalatnai A, Galambos E, Perjési E. Importance of Immunohistochemical Detection of Somatostatin Receptors. Pathol Oncol Res 2019;25:521-5. [DOI: 10.1007/s12253-018-0426-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Lattuada D, Casnici C, Venuto A, Marelli O. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. Journal of Neuroimmunology 2002;133:211-6. [DOI: 10.1016/s0165-5728(02)00364-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Pan Q, Li DG, Lu HM, Lu LY, Wang YQ, Xu QF. Antiproliferative and proapoptotic effects of somatostatin on activated hepatic stellate cells. World J Gastroenterol 2004;10:1015-8. [PMID: 15052685 DOI: 10.3748/wjg.v10.i7.1015] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
47 Lang F, Föller M, Lang K, Lang P, Ritter M, Vereninov A, Szabo I, Huber SM, Gulbins E. Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol 2007;428:209-25. [PMID: 17875419 DOI: 10.1016/S0076-6879(07)28011-5] [Cited by in Crossref: 135] [Cited by in F6Publishing: 62] [Article Influence: 9.6] [Reference Citation Analysis]
48 Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-guibert J, Pyronnet S, Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends in Endocrinology & Metabolism 2014;25:115-27. [DOI: 10.1016/j.tem.2013.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
49 Öberg K. Somatostatin analog octreotide LAR ® in gastro–entero–pancreatic tumors. Expert Review of Anticancer Therapy 2014;9:557-66. [DOI: 10.1586/era.09.26] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
50 Evangelou I, Petraki C, Msaouel P, Scorilas A, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. Eur J Clin Invest 2012;42:777-83. [PMID: 22304674 DOI: 10.1111/j.1365-2362.2012.02648.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
51 Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2010;50:137-84. [PMID: 19859675 DOI: 10.1007/400_2009_29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 0.9] [Reference Citation Analysis]
52 Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230-237. [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 8.0] [Reference Citation Analysis]
53 Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009;12:297-303. [PMID: 19330452 DOI: 10.1007/s11102-009-0175-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
54 Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid H, Marelli O. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. Journal of Neuroimmunology 2007;182:153-9. [DOI: 10.1016/j.jneuroim.2006.10.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
55 Ludvigsen E, Carlsson C, Tiensuu Janson E, Sandler S, Stridsberg M. Somatostatin receptor 1-5; expression profiles during rat development. Ups J Med Sci 2015;120:157-68. [PMID: 25926390 DOI: 10.3109/03009734.2015.1035413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
56 Kumar M, Liu ZR, Thapa L, Wang DY, Tian R, Qin RY. Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2. Pancreas. 2004;29:141-151. [PMID: 15257106 DOI: 10.1097/00006676-200408000-00009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
57 Fjällskog M, Janson ET. Treatment of endocrine pancreatic tumors. Acta Oncologica 2009;44:329-38. [DOI: 10.1080/02841860510029941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]